Mac‐2‐binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C
Kazuhito Kawata, Masanori Atsukawa, Kazuyoshi Ohta, Takeshi Chida, Hidenao Noritake, Taeang Arai, Katsuhiko Iwakiri, Satoshi Yasuda, Hidenori Toyoda, Tomomi Okubo, Atsushi Hiraoka, Tsunamasa Watanabe, Haruki Uojima, Akito Nozaki, Joji Tani, Asahiro Morishita, Fujito Kageyama, Yuzo Sasada, Masamichi Nagasawa, Masahiro Matsushita, Tatsuki Oyaizu, Shigeru Mikami, Tadashi Ikegami, Hiroshi Abe, Kentaro Matsuura, Yasuhito Tanaka, Akihito Tsubota – 27 March 2022 – Despite reports of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection after achieving sustained